Zevra Therapeutics Inc. (ZVRA) made headlines yesterday with a landmark FDA approval for its innovative drug, MIPLYFFA, in the treatment of Niemann-Pick disease type C. The regulatory development not only offers new hope for patients with this ultra-rare and progressive neurodegenerative disease but has also propelled Zevra shares to a new 52-week high.
In addition to ZVRA, a couple of stocks we featured on our site also touched new 52-week highs yesterday.
*Last Closing Price refers to the stock's closing price on Sep.20, 2024.
Ticker
Published Date
Published Price
Maximum Price Since Publication
*Last Closing Price
Maximum Gain %
Zevra Therapeutics Inc. (ZVRA)
Aug.26, 2024
$7.21
$8.81
$8.06
22%
Arcellx Inc. (ACLX)
June 3, 2022
$12.66
$88.17
$86.61
596%
Rockwell Medical Inc. (RMTI)
Sep.4, 2024
$3.21
$4.57
$4.40
42%
Catalyst Pharmaceuticals Inc. (CPRX)
Feb.13, 2024
$13.32
$21.67
$20.79
62%
ADMA Biologics Inc. (ADMA)
Feb.15, 2024
$5.36
$20.16
$19.98
276%
Zymeworks Inc. (ZYME)
Oct.9, 2023
$6.38
$13.23
$13.09
107%
The Pennant Group Inc. (PNTG)
Feb.7, 2023
$12.38
$36.33
$35.68
193%
Travere Therapeutics Inc. (TVTX)
Aug.14, 2024
$8.91
$15.26
$15.21
71%
Related Reading
EWTX Yields Over 300% Returns, ADMA Records 200% Gains - Did You Strike While The Iron Is Hot?
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.